In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results